BGI is dedicated to utilizing genomics in order to advance precision medicine for cancer. BGI’s next-generation sequencing assays offer a variety of options, including targeted panels that analyze genes directly linked to specific cancers by well documented scientific research, and also much larger cancer panels designed for cancer analysis and discovery.
BGI’s cancer panels are designed to identify all four classes of actionable genomic alterations, including base substitutions, insertions and deletions, copy number alterations and selected fusions.
Colorectal cancer is the second leading cause of cancer-related mortality in the United States. BGI uses target region capture and NGS to examine 7 genes implicated in CRC targeted therapies, including those recommended in the latest NCCN guidelines.
Patients identified with colorectal cancer
6 working days
Fresh/Frozen Tumor tissue, biopsy, FFPE, DNA
Target region capture, High-throughput sequencing
Ordering the BGI SENTIS™ Colorectal Cancer (CRC) Panel is easy.
Physician orders test
Blood or saliva sample collected
Sample shipped to BGI and analyzed
Results sent to physician